Xience has also won praise for its ease of delivery. Endeavor, meanwhile, has shown almost no risk of blood clots whatsoever. Boston Scientific won't miss out on the new wave entirely, though. Xience comes from technology developed by Guidant, and Boston Scientific had to sell it off to Abbott as a condition of the Guidant acquisition. But that deal allows Boston Scientific to sell a copy of Xience called Promus in some markets. And both Taxus and J&J's Cypher have shown effectiveness in high-risk patients, such as those with diabetes, so they may not lose much if any ground in that part of the market.
0 comments
Hide comments
